Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 728-733    DOI: 10.12892/ejgo4593.2019
Original Research Previous articles | Next articles
Adenocarcinoma of the cervix: its prognosis and difficult pathological diagnosis
H. Oikiri1, M. Futagami1, J. Watanabe2, Y. Yokoyama1, *()
1Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Japan
2Department of Cellular and Hist-Pathology, Division of Medical Life Science, Hirosaki University Graduate School of Health Science, Hirosaki, Aomori, Japan
Download:  PDF(4288KB)  ( 127 ) Full text   ( 8 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose of investigation: Adenocarcinoma (AC) of the cervix is considered to have a worse prognosis than squamous cell carcinoma (SCC). The incidence of AC of the cervix has increased over the past few years. The WHO’s classification of AC of the cervix was revised in 2014, and usual-type endocervical AC and gastric-type mucinous AC were added as new classes of AC of the cervix. The current study reassessed AC of the cervix in accordance with the new classification and it examined the prognosis for AC of the cervix. Materials and Methods: Subjects were 204 patients who were diagnosed with cervical cancer at this Hospital from 2001 to 2011. Age at onset, histology, FIGO’s staging classification, treatment, and the five-year survival rate for these patients were examined retrospectively. The histopathology of cancer previously identified as AC was reassessed in accordance with the 2014 WHO classification of AC of the cervix. Results: SCC was identified in 165 patients (81%), AC was identified in 22 (11%), adenosquamous carcinoma (ASC) was identified in nine (4%), and some other form of cancer was identified in eight (4%). Median age at onset was 52 years for patients with SCC and 44 years for patients with AC/ASC. According to FIGO’s staging classification, SCC was Stage I in 79 patients (48%) and AC/ASC was Stage I in 21 patients (68%), SCC was Stage II in 41 patients (25%), AC/ASC was Stage II in five patients (16%), SCC was Stage III in 28 patients (17%), AC/ASC was Stage III in one patient (3%), SCC was Stage IV in 16 patients (10%) and AC/ASC was Stage IV in four patients (13%). The five-year survival rate (Kaplan-Meier method) was 89.3% for patients with SCC undergoing initial surgery and 91.7% for patients with AC/ASC undergoing initial surgery. The five-year survival rate for patients undergoing initial surgery did not differ significantly (log-rank test, p=0.84). The 5-year survival rate was 92% for patients with Stage I-II AC/ASC who underwent surgery and 50% for patients with Stage I-II AC/ASC who received radiation therapy (including concurrent chemotherapy and radiation therapy). The five-year survival rate for patients with Stage I-II AC/ASC differed significantly depending on whether the patient underwent surgery or not (p < 0.02). Reassessment of AC resulted in a different diagnosis in eight (38%) of 21 patients with AC. Reassessment in this study resulted in six patients who were diagnosed with endometrioid AC all being diagnosed with usual-type endocervical AC instead. Conclusion: AC/ASC is considered to have a poor prognosis, but the current results suggested that surgery can result in a good prognosis if lesions can be removed. The histopathologic subtype of AC is often determined by a diagnostician, and this determination is difficult.

Key words:  Adenocarcinoma of the cervix      Usual-type endocervical adenocarcinoma      Five-year survival rate      Surgery     
Published:  10 October 2019     
*Corresponding Author(s):  Y. YOKOYAMA     E-mail:  yokoyama@hirosaki-u.ac.jp

Cite this article: 

H. Oikiri, M. Futagami, J. Watanabe, Y. Yokoyama. Adenocarcinoma of the cervix: its prognosis and difficult pathological diagnosis. European Journal of Gynaecological Oncology, 2019, 40(5): 728-733.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4593.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/728

[1] Sarita Kumari, Jai Bhagwan Sharma. Recurrent immature teratoma in a 47 year old with maturation in subsequent laparotomies and a grave course[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 813-816.
[2] Rie Nakamura, Yuko Shimoji, Tadaharu Nakasone, Yusuke Taira, Yoshihisa Arakaki, Tomoko Nakamoto, Keiko Mekaru, Wataru Kudaka, Tatsuya Kinjo, Yoichi Aoki. Malignant bowel obstruction in recurrent gynecologic cancers: who will benefit from palliative surgical intervention?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 513-516.
[3] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[4] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[5] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[6] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[7] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[8] Cheng-Wei Wang, Ching-Hui Chen, Wei-Min Liu. Incidental small ovarian surface serous carcinoma with Miliary abdominal seeding during robotically-assisted total hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 654-656.
[9] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[10] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[11] L. Nejković, J. Stulić, I. Rudić Biljić Erski, A. Ristić, R. Aničić, M. Vasiljević. Preserving fertility in patients with granulosa cell tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 462-464.
[12] Nozomu Yanaihara, Chihiro Sato, Masami Iwamoto, Kazu Ueda, Aikou Okamoto. Juvenile ovarian mature teratoma with malignant transformation diagnosed after laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 465-467.
[13] T. Armeanu, R. Maftei, G. Simionescu, D. Nicolaiciuc, N. Plopa, B. Doroftei. Infertility and borderline malignant ovarian tumors: a case of successful pregnancy after fertility-preserving management of the disease[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 284-288.
[14] C. Fang, J. Yang, W. Ding, K. Li, D. Weng, P. Wu, G. Chen, D. Ma, J. Wei. Incidence of symptomatic deep vein thrombosis after gynecological surgery: a retrospective study in Chinese population[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 939-942.
[15] S.H. Nam, H.R. Yang, D. Kang, K.O. Jung, W.Y. Kim. Survival of advanced epithelial ovarian/fallopian tube/primary peritoneum carcinoma after high-complexity upper abdominal surgery[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 970-976.
No Suggested Reading articles found!